A patient picks up a prescription and is told the price is $450. The same drug at another pharmacy costs $60 with a discount card, while a neighbor with a different insurance plan pays $25. Meanwhile, the manufacturer’s list price was $900, and the company’s net revenue per prescription may be closer to $400. Four different numbers describe one pill, and none of them is simply “the price.”
That confusion sits at the center of the debate over prescription drug costs in America. Surveys from KFF have repeatedly found that roughly one in four adults say they have difficulty affording their prescriptions, and about three in ten report skipping, cutting, or delaying doses because of cost at some point. At the same time, spending on medicines keeps climbing, driven by new high priced therapies, including GLP-1 drugs for diabetes and obesity.
No single villain explains this. The U.S. system layers manufacturers, wholesalers, pharmacy benefit managers (PBMs), insurers, pharmacies, and government programs, each with its own incentives and each taking a share. This guide explains how pricing works, why America differs from other countries, what PBMs do, how generics and biosimilars change the picture, what recent Medicare policy has changed, and who bears the cost. Because the policy landscape is moving, all dates, prices, and program details should be verified against CMS and other primary sources at publication.
How Prescription Drug Prices Are Structured
List Price Versus Net Price
The list price, formally the wholesale acquisition cost (WAC), is the price a manufacturer sets before discounts. It works like a sticker price. The net price is what the manufacturer actually receives after rebates, discounts, and fees. For many brand drugs, the gap between the two, sometimes called the gross to net bubble, has grown to tens of billions of dollars a year.
Rebates
Manufacturers often pay rebates to PBMs and insurers in exchange for favorable placement on formularies, the lists of covered drugs. Rebates can reduce net prices by 30 to 60 percent or more for some drugs, especially in competitive classes such as insulin. Because patient cost sharing is often based on list price, a patient paying a percentage of the sticker price may not benefit from the rebate that lowered the insurer’s cost.
Insurers, PBMs and Pharmacies
PBMs negotiate with manufacturers and pharmacies on behalf of insurers and employers. Pharmacies buy from wholesalers and dispense to patients, receiving reimbursement and a dispensing fee. Each step can involve spread, fees, or markups that are not visible to the patient.
Patient Cost Sharing
Patients meet deductibles first, then pay copays or coinsurance. In a high deductible plan, a person may pay the full negotiated price until the deductible is met. Manufacturer assistance programs, such as copay cards, can reduce costs for commercially insured patients but are generally prohibited for people in federal programs such as Medicare because of anti kickback rules.
Table 1: The U.S. Drug Pricing Chain
| Step | Who is involved | What happens | Who may profit or be affected |
|---|---|---|---|
| Manufacturing and pricing | Drug manufacturer | Sets list price (WAC) | Manufacturer revenue and research funding |
| Distribution | Wholesalers | Buy from manufacturers, sell to pharmacies | Small percentage margin, high volume |
| Formulary negotiation | PBMs and insurers | Rebates exchanged for coverage placement | PBMs, insurers, manufacturers |
| Dispensing | Pharmacies | Fill prescriptions, collect copays | Pharmacy reimbursement, dispensing fees |
| Payment | Insurers, employers, government | Reimburse pharmacies | Premiums, taxpayers |
| Patient cost | Patients | Deductibles, copays, coinsurance | Out of pocket costs |
Why U.S. Drug Prices Differ From Other Countries
Americans pay more for brand name drugs than patients in nearly every other wealthy country. A RAND Corporation analysis found that U.S. prices across all drugs averaged about 2.8 times those in 33 other high income countries in 2022, with brand name drugs priced at more than four times the comparison countries. Generics, by contrast, were cheaper in the United States than abroad.
Negotiation Structures
Most other wealthy countries use central bodies to negotiate or set prices, often tied to measured clinical benefit. The U.S. historically relied on fragmented negotiation among private payers. Medicare was barred from negotiating directly until the Inflation Reduction Act of 2022.
Market Organization and Purchasing Power
The U.S. has multiple payers rather than a single national purchaser, which dilutes bargaining power for many drugs. Countries with single payers can walk away from a price, as drug makers fear losing a whole national market.
Patents and Exclusivity
Patents typically last 20 years from filing, and regulatory exclusivities can add protection. Manufacturers also seek additional patents on formulations, delivery devices, and methods of use, sometimes called patent thickets. These delay generic competition and extend the period of high prices.
Regulation and Innovation Funding
Industry argues that higher U.S. prices fund a large share of global pharmaceutical research and that price controls abroad reduce innovation. Critics counter that much early research is funded by the National Institutes of Health and that companies spend heavily on marketing and shareholder returns. Economists generally agree that prices influence investment, though the size of that effect is debated.
Table 2: International Pricing Methodology Comparison
| Country or system | Typical approach | Effect on prices |
|---|---|---|
| United States | Private negotiation, limited Medicare negotiation since 2026 | Highest brand prices |
| United Kingdom | NICE cost effectiveness review, NHS negotiation | Lower, with access limits for some drugs |
| Germany | Early benefit assessment then negotiated price | Moderate |
| France | Price negotiated based on added benefit | Lower |
| Canada | Federal price review plus provincial negotiation | Lower |
| Japan | Government sets prices and revises them regularly | Lower |
The Role of PBMs
Pharmacy benefit managers administer prescription drug benefits for health plans. They process claims, build pharmacy networks, manage formularies, and negotiate rebates. Three firms, CVS Caremark, Express Scripts (Cigna), and Optum Rx (UnitedHealth), together handle roughly 80 percent of prescription claims in the U.S., according to Federal Trade Commission reports.
Criticisms
Critics argue that PBMs profit from keeping list prices and rebates high, since their revenue can rise with list price, and that vertical integration with insurers and pharmacies creates conflicts of interest. FTC interim staff reports in 2024 and 2025 described how large PBMs steered business to affiliated pharmacies and marked up certain specialty generics. The FTC has also pursued a case related to insulin rebating practices.
Defenses and Nuance
PBMs state that they lower costs by negotiating discounts and passing most rebates to plan sponsors. Reasonable people can conclude that PBMs both create savings and contribute to opaque pricing. Not every pricing outcome is attributable to PBMs. Manufacturers set list prices, patents block competition, and benefit design determines what patients pay. Several states and federal proposals aim to require delinking of PBM compensation from list price and greater transparency.
Brand Drugs, Generics and Biosimilars
Generics
Generic drugs account for about 90 percent of U.S. prescriptions but only roughly 13 to 18 percent of spending, according to industry and IQVIA data. When multiple generic makers compete, prices can fall by 80 to 90 percent from the brand price. Problems appear when manufacturers exit markets, causing shortages and price spikes.
Brand Drugs
Brands make up a small share of prescriptions but a large majority of spending. Specialty drugs for cancer, autoimmune disease, and rare conditions can cost tens of thousands of dollars annually or far more.
Biosimilars
Biosimilars are highly similar versions of biologic drugs. They typically enter at discounts of 15 to 50 percent or more, and uptake depends on formulary design. The market for adalimumab (Humira) saw a slow start for biosimilars after 2023, followed by faster adoption when large PBMs launched private label versions and changed formulary preferences.
Table 3: Brand, Generic and Biosimilar Pricing Differences
| Feature | Brand | Generic | Biosimilar |
|---|---|---|---|
| Share of prescriptions | About 10 percent | About 90 percent | Small but growing |
| Share of spending | Large majority | Roughly 13 to 18 percent | Small |
| Typical price effect | Highest | 80 to 90 percent below brand when competitive | Moderately below reference biologic |
| Approval pathway | FDA new drug or biologic approval | Abbreviated approval | Abbreviated biologic pathway |
| Main barrier to price drops | Patents and exclusivities | Few competitors for some drugs | Formulary design, patent disputes |
Medicare Drug Price Negotiation and Recent Policy Changes
The Inflation Reduction Act (IRA) of 2022 created several changes in Medicare. Because this is a fast moving area, readers should verify implementation details with the Centers for Medicare and Medicaid Services (CMS).
Negotiation Program
Medicare can now negotiate prices for selected high spending drugs. The first ten drugs, including Eliquis, Jardiance, Xarelto, Januvia, Farxiga, Entresto, Enbrel, Imbruvica, Stelara, and NovoLog products, had negotiated prices take effect on January 1, 2026. A second round of 15 drugs, including semaglutide products such as Ozempic, Wegovy, and Rybelsus, was selected for negotiated prices that take effect January 1, 2027. A third round, which for the first time includes drugs covered under Medicare Part B, was selected for prices effective in 2028. CMS has reported that negotiated prices would have saved Medicare billions of dollars in the first cycle compared with list prices.
Out of Pocket Cap and Insulin
Starting in 2025, Medicare Part D enrollees have an annual out of pocket cap, set at $2,000 in 2025 and indexed to rise modestly in later years. Insulin copays are capped at $35 per month for Medicare enrollees. In 2023, the three largest insulin makers announced list price cuts and voluntary copay caps in the commercial market.
Other Initiatives
The administration has also announced pricing agreements with several manufacturers tied to a most favored nation approach and a federal website for direct to consumer purchases. The details and durability of these arrangements continue to evolve and should be confirmed from current sources.
Who Bears the Cost?
Cost does not fall equally on everyone. The same drug can be nearly free for one person and unaffordable for another.
Uninsured patients often face list prices, though discount cards, generics, and manufacturer programs can help.
High deductible plan members pay full negotiated prices until reaching the deductible, creating cost barriers early in the year.
Medicare beneficiaries have gained from the out of pocket cap and insulin limits but may still face high costs for drugs not yet covered by negotiation.
Employers pay a large share of costs through premiums and pass some on to workers.
Insurers manage costs through formularies, prior authorization, and step therapy.
Government programs such as Medicaid receive mandatory rebates, and taxpayers fund Medicare, Medicaid, and the Veterans Health Administration.
Table 4: Major Affordability Mechanisms and Eligibility
| Mechanism | Who qualifies | What it does | Limits |
|---|---|---|---|
| Medicare Part D out of pocket cap | Medicare Part D enrollees | Caps yearly spending | Cap amount indexed over time |
| Medicare insulin copay cap | Medicare enrollees | $35 monthly insulin copay | Applies to covered insulins |
| Manufacturer copay cards | Commercially insured patients | Lower copay for brand drug | Not allowed for federal program enrollees, may end |
| Patient assistance programs | Low income uninsured or underinsured | Free or low cost drug | Income limits, paperwork |
| Medicaid | Eligible low income people | Low or no copays | State rules vary |
| 340B program | Eligible safety net providers | Discounted drugs for providers | Benefits flow to providers, not always patients |
| Discount cards and cash price tools | Anyone | May beat insurance price for generics | Spending may not count toward deductible |
What Patients Can Do About High Medication Costs
Ask whether a generic or biosimilar exists. Compare prices across pharmacies, including online and cash price programs, and check whether paying cash is cheaper than using insurance. Ask the prescriber about therapeutic alternatives and 90 day supplies. Review the plan formulary each year during open enrollment, since coverage and tiers change.
People with low incomes can apply for manufacturer patient assistance programs or state pharmaceutical assistance. Medicare enrollees can compare Part D plans and review Extra Help eligibility. Anyone struggling to pay should tell their doctor, because skipping doses can be more dangerous and expensive than a change in prescription. A pharmacist can often suggest practical options.
The Bigger Picture
America’s drug cost problem has several layers: high launch prices for new drugs, delayed competition, complex rebate arrangements, and benefit designs that expose patients to list prices. Policy fixes target different layers, from Medicare negotiation to PBM reform to faster generic and biosimilar entry. Each has trade offs, including effects on innovation, access, and administrative complexity.
Readers who follow the debate should keep three numbers distinct: list price, negotiated net price, and patient out of pocket cost. Mixing them leads to misleading conclusions. Over the coming years, the effects of Medicare negotiation, PBM reform proposals, and the spread of biosimilars will shape whether the system moves toward lower and more transparent prices. Patients and policymakers alike will benefit from clear data and honest accounting of who pays what.
Three Patients, Three Different Prices
Abstract pricing chains become clearer through examples. The following scenarios are illustrative, and the numbers are simplified, not drawn from a specific product.
Patient one: commercially insured, high deductible plan.
A 45 year old with a high deductible health plan is prescribed a brand name inhaler with a list price of $400 per month. The insurer’s negotiated price is $320, but the patient has not met a $3,000 deductible in January, so they pay the full $320 until the deductible is met. A manufacturer copay card might reduce the cost to $50 for the first months, though such cards do not apply to Medicare and may be limited by accumulator programs that stop copay card dollars from counting toward the deductible. In July, after meeting the deductible, the patient’s share drops to a $40 copay.
Patient two: Medicare Part D enrollee.
A 70 year old takes several brand drugs for diabetes and heart disease. Before 2025, the patient could face a coverage gap with high costs and no cap on catastrophic spending. Under the Inflation Reduction Act, the annual out of pocket limit in Part D now caps spending, and a $35 monthly limit applies to covered insulin. If one of the patient’s drugs is among those with Medicare negotiated prices, the price paid by the plan and any coinsurance based on it falls. The patient can also smooth costs through the Medicare Prescription Payment Plan, which spreads out of pocket spending across the year.
Patient three: uninsured.
A 32 year old without insurance needs a generic blood pressure medication. The pharmacy’s usual cash price is $45 for a month, but a discount card or a low price program lists the same drug at $8. The patient also qualifies for a community health center with a sliding fee pharmacy. For a brand drug, the same patient might be offered a manufacturer assistance program that provides free medication based on income, with paperwork and renewal requirements.
These examples show a key point. Drug pricing is not a single price tag, and the same medication can cost a person nothing or hundreds of dollars depending on coverage, timing, pharmacy choice, and program eligibility. Patients who ask about generics, cash prices, assistance programs, and plan formularies often pay far less. Policymakers face a related problem: reforms that lower list prices may not help patients whose cost sharing is set by deductibles and coinsurance, and reforms that lower out of pocket spending may shift costs to premiums or taxpayers. Understanding the layers helps readers judge proposals and navigate care.
Medical Disclaimer
This article is for general information and is not medical, legal, or financial advice. Do not stop or change medication without consulting a prescriber. Insurance coverage and prices vary, so verify details with your plan and pharmacist.
FAQ
Q: Why are prescription drugs so expensive in the U.S.?
A: Multiple factors combine: high launch prices, patent protections that delay competition, fragmented negotiation, rebate and PBM structures, and benefit designs that expose patients to list prices. No single cause explains everything.
Q: Why are generic drugs cheaper?
A: Generic makers do not repeat expensive clinical trials and compete with each other once patents expire. With several competitors, prices can fall 80 to 90 percent below the brand price.
Q: What do PBMs do?
A: Pharmacy benefit managers process drug claims, negotiate rebates and pharmacy networks, and manage formularies for insurers and employers. They are criticized for opacity and conflicts of interest and defended as cost negotiators.
Q: How does Medicare negotiate drug prices?
A: Under the Inflation Reduction Act, CMS selects certain high spending drugs and negotiates prices with manufacturers. The first negotiated prices took effect in January 2026, with more drugs added in 2027 and 2028.
Q: Why can the same drug cost different amounts?
A: Prices vary by insurance plan, deductible status, pharmacy, formulary tier, and whether a discount card or cash price is used. Negotiated prices differ by payer.
Q: What can patients do about high medication costs?
A: Ask about generics, compare pharmacy prices, use assistance programs, review plan formularies each year, and talk to the prescriber about alternatives.
Q: What is the difference between list price and net price?
A: List price is the manufacturer’s sticker price. Net price is what the manufacturer receives after rebates and discounts. Patient cost may depend on either.
Q: Are biosimilars cheaper?
A: Usually, with discounts ranging from 15 percent to more than 50 percent compared with the original biologic. Uptake depends on insurer and PBM formulary decisions.
Q: Does Medicare cap out of pocket drug costs?
A: Yes. Part D has an annual out of pocket cap that started at $2,000 in 2025 and rises with indexing, plus a $35 monthly cap on covered insulin.